|
1
|
Didkowska J, Wojciechowska U and Zatoński
W: Cancer in Poland in 2011. National M. Sklodowska-Curie Cancer
Center; Warsaw: pp. 13–21. 2012
|
|
2
|
Ferlay J, Steliarova-Foucher E,
Lortet-Tieulent J, et al: Cancer incidence and mortality patterns
in Europe: estimates for 40 countries in 2012. Eur J Cancer.
49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Potischman N, Hoover RN, Brinton LA, et
al: Case-control study of endogenous steroid hormones and
endometrial cancer. J Natl Cancer Inst. 88:1127–1135. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lax SF, Pizer ES, Ronnett BM and Kurman
RJ: Comparison of estrogen and progesterone receptor, Ki-67, and
p53 immunoreactivity in uterine endometrioid carcinoma and
endometrioid carcinoma with squamous, mucinous, secretory, and
ciliated cell differentiation. Hum Pathol. 29:924–931. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lax SF: Molecular genetic pathways in
various types of endometrial carcinoma: from a phenotypical to a
molecular-based classification. Virchows Arch. 444:213–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu FS: Molecular carcinogenesis of
endometrial cancer. Taiwan J Obstet Gynecol. 46:26–32. 2007.
View Article : Google Scholar
|
|
8
|
Wu H, Goel V and Haluska FG: PTEN
signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Semczuk A, Berbeć H, Kostuch M, Cybulski
M, Wojcierowski J and Baranowski W: K-ras gene point
mutations in human endometrial carcinoma: correlation with
clinicopathological features and patients’ outcome. J Cancer Res
Clin Oncol. 124:695–700. 1998.
|
|
10
|
Egeblad M and Werb Z: New functions for
the matrix metalloproteinases in cancer progression. Nat Rev
Cancer. 2:163–174. 2002. View
Article : Google Scholar
|
|
11
|
Duffy MJ, Maguire TM, Hill A, McDermott E
and O’Higgins N: Metalloproteinases: role in breast carcinogenesis,
invasion and metastasis. Breast Cancer Res. 2:252–257. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
McCawley LJ and Matrisian LM: Matrix
metalloproteinases: multifunctional contributors to tumor
progression. Mol Med Today. 6:149–156. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nabeshima K, Inoue T, Shimao Y and
Sameshima T: Matrix metalloproteinases in tumor invasion: role for
cell migration. Pathol Int. 52:255–264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gimona M: The microfilament system in the
formation of invasive adhesions. Semin Cancer Biol. 18:23–34. 2008.
View Article : Google Scholar
|
|
15
|
Rhodes JM and Simons M: The extracellular
matrix and blood vessel formation: not just a scaffold. J Cell Mol
Med. 11:176–205. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vanacore RM, Shanmugasundararaj S,
Friedman DB, Bondar O, Hudson BG and Sundaramoorthy M: The α1.α2
network of collagen IV. Reinforced stabilization of the
noncollagenous domain-1 by noncovalent forces and the absence of
Met-Lys cross-links. J Biol Chem. 279:44723–44730. 2004.
|
|
17
|
Aumailley M, Nurcombe V, Edgar D, Paulsson
M and Timpl R: The cellular interactions of laminin fragments. Cell
adhesion correlates with two fragment-specific high affinity
binding sites. J Biol Chem. 262:11532–11538. 1987.PubMed/NCBI
|
|
18
|
Erickson AC and Couchman JR: Still more
complexity in mammalian basement membranes. J Histochem Cytochem.
48:1291–1306. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Girós A, Morante J, Gil-Sanz C, Fairén A
and Costell M: Perlecan controls neurogenesis in the developing
telencephalon. BMC Dev Biol. 5:292007.PubMed/NCBI
|
|
20
|
Pankov R and Yamada KM: Fibronectin at a
glance. J Cell Sci. 115:3861–3863. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin H, Jo S and Mikos AG: Biomimetic
materials for tissue engineering. Biomaterials. 24:4353–4364. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ohtsuka S, Iwase K, Kato M, et al: An mRNA
amplification procedure with directional cDNA cloning and
strand-specific cRNA synthesis for comprehensive gene expression
analysis. Genomics. 84:715–729. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gamberoni G, Storari S and Volinia S:
Finding biological process modifications in cancer tissues by
mining gene expression correlations. BMC Bioinformatics. 9:62006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ewis AA, Zhelev Z, Bakalova R, et al: A
history of microarrays in biomedicine. Expert Rev Mol Diagn.
5:315–328. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Braunschweig T, Chung JY and Hewitt SM:
Tissue microarrays: bridging the gap between research and the
clinic. Expert Rev Proteomics. 2:325–336. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Smid-Koopman E, Blok LJ, Helmerhorst TJ,
et al: Gene expression profiling in human endometrial cancer tissue
samples: utility and diagnostic value. Gynecol Oncol. 93:292–300.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Skandalis SS, Theocharis AD, Vynios DH, et
al: Cartilage aggrecan undergoes significant compositional and
structural alterations during laryngeal cancer. Biochim Biophys
Acta. 1760:1046–1053. 2006. View Article : Google Scholar
|
|
28
|
East CJ, Stanton H, Golub SB, Rogerson FM
and Fosang AJ: ADAMTS-5 deficiency does not block aggrecanolysis at
preferred cleavage sites in the chondroitin sulfate-rich region of
aggrecan. J Biol Chem. 282:8632–8640. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Eshchenko TY, Rykova VI, Chernakov AE,
Sidorov SV and Grigorieva EV: Expression of different proteoglycans
in human breast tumors. Biochemistry. 72:1016–1020. 2007.PubMed/NCBI
|
|
30
|
Matsui Y, Araki N, Tsuboi H, et al:
Differential expression of aggrecan mRNA isoforms by chondrosarcoma
cells. Anticancer Res. 22:4169–4172. 2002.PubMed/NCBI
|
|
31
|
Albelda SM: Role of integrins and other
cell adhesion molecules in tumor progression and metastasis. Lab
Invest. 68:4–17. 1993.PubMed/NCBI
|
|
32
|
Albelda SM, Mette SA, Elder DE, et al:
Integrin distribution in malignant melanoma: association of the
β3 subunit with tumor progression. Cancer Res.
50:6757–6764. 1990.
|
|
33
|
Lessey BA, Albelda S, Buck CA, et al:
Distribution of integrin cell adhesion molecules in endometrial
cancer. Am J Pathol. 146:717–726. 1995.PubMed/NCBI
|
|
34
|
Castelbaum AJ, Ying L, Somkuti SG, Sun J,
Ilesanmi AO and Lessey BA: Characterization of integrin expression
in a well differentiated endometrial adenocarcinoma cell line
(Ishikawa). J Clin Endocrinol Metab. 82:136–142. 1997.PubMed/NCBI
|
|
35
|
Lessey BA, Castelbaum AJ, Sawin SW, et al:
Aberrant integrin expression in the endometrium of women with
endometriosis. J Clin Endocrinol Metab. 79:643–649. 1994.PubMed/NCBI
|
|
36
|
Chiquet-Ehrismann R: Tenascins. Int J
Biochem Cell Biol. 36:986–990. 2004. View Article : Google Scholar
|
|
37
|
Wehrle B and Chiquet M: Tenascin is
accumulated along developing peripheral nerves and allows neurite
outgrowth in vitro. Development. 110:401–415. 1990.PubMed/NCBI
|
|
38
|
Tucker RP: Abnormal neural crest cell
migration after the in vivo knockdown of tenascin-C expression with
morpholino antisense oligonucleotides. Dev Dyn. 222:115–119. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Joester A and Faissner A: The structure
and function of tenascins in the nervous system. Matrix Biol.
20:13–22. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zacharias U, Leuschner R, Nörenberg U and
Rathjen FG: Tenascin-R induces actin-rich microprocesses and
branches along neurite shafts. Mol Cell Neurosci. 21:626–633. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Becker CG, Schweitzer J, Feldner J, Becker
T and Schachner M: Tenascin-R as a repellent guidance molecule for
developing optic axons in zebrafish. J Neurosci. 23:6232–6237.
2003.PubMed/NCBI
|
|
42
|
Fox JW, Mayer U, Nischt R, et al:
Recombinant nidogen consists of three globular domains and mediates
binding of laminin to collagen type IV. EMBO J. 10:3137–3146.
1991.PubMed/NCBI
|
|
43
|
Chung AE, Dong LJ, Wu C and Durkin ME:
Biological functions of entactin. Kidney Int. 43:13–19. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kimura N, Toyoshima T, Kojima T and
Shimane M: Entactin-2: a new member of basement membrane protein
with high homology to entactin/nidogen. Exp Cell Res. 241:36–45.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yelian FD, Edgeworth NA, Dong LJ, Chung AE
and Armant DR: Recombinant entactin promotes mouse primary
trophoblast cell adhesion and migration through the Arg-Gly-Asp
(RGD) recognition sequence. J Cell Biol. 121:923–929.
1993.PubMed/NCBI
|
|
46
|
Oivula J, Lohi J, Tani T, et al: Renal
cell carcinomas and pancreatic adenocarcinomas produce nidogen in
vitro and in vivo. J Pathol. 187:455–461. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Shuttleworth CA: Type VIII collagen. Int J
Biochem Cell Biol. 29:1145–1148. 1997. View Article : Google Scholar
|
|
48
|
Hou G, Mulholland D, Gronska MA and
Bendeck MP: Type VIII collagen stimulates smooth muscle cell
migration and matrix metalloproteinase synthesis after arterial
injury. Am J Pathol. 156:467–476. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rüger B, Dunbar PR, Hasan Q, et al: Human
mast cells produce type VIII collagen in vivo. Int J Exp Pathol.
75:397–404. 1994.
|
|
50
|
Halsted KC, Bowen KB, Bond L, et al:
Collagen α1(XI) in normal and malignant breast tissue. Mod Pathol.
21:1246–1254. 2008.
|
